Physician profile
Sheldon Junior Mckenzie
NPI 1164772281
$1,593.04
in general payments reported to CMS, 2019-2025
24 companies · $314 in 2025
The $314 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $10.82 · 2020: $81.38 · 2022: $123 · 2023: $386 · 2024: $678 · 2025: $314.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,333 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,332.51 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $214.85 | 2022-2025 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $184.92 | 2022-2025 | Mounjaro, Zepbound, Humulin |
| Tandem Diabetes Care, INC. | $160.99 | 2020-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Astrazeneca Pharmaceuticals LP | $133.99 | 2024 | Farxiga |
| Abbott Laboratories | $132.21 | 2023-2024 | Freestyle Libre 3 |
| Medtronic, INC. | $111.64 | 2023-2024 | Minimed 780g |
| Novo Nordisk INC | $83.40 | 2022-2024 | Rybelsus, Ozempic |
| Amgen INC. | $82.94 | 2024-2025 | Tepezza |
| Insulet Corporation | $66.65 | 2024-2025 | Omnipod |
| Radius Health, INC. | $55.81 | 2022-2025 | Tymlos |
| Alexion Pharmaceuticals, INC. | $46.05 | 2024 | Strensiq |
| Astellas Pharma US INC | $45.51 | 2024-2025 | Veozah |
| Abbvie INC. | $34.10 | 2023-2024 | |
| Mallinckrodt Hospital Products INC. | $27.19 | 2022 | |
| Cequr Corporation | $26.72 | 2023-2024 | Cequr Simplicity |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ascendis Pharma Endocrinology INC | $26.42 | 2025 | Yorvipath |
| Beta Bionics, INC. | $26.01 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Amryt Pharma Holdings LTD | $23.52 | 2023 | Mycapssa |
| Mannkind Corporation | $22.19 | 2023 | Afrezza |
| Chiesi USA, INC. | $20.48 | 2024 | Mycapssa |
| Sanofi-Aventis U.S. LLC | $19.16 | 2023 | |
| Ascensia Diabetes Care US INC. | $18.81 | 2025 | |
| Horizon Therapeutics Plc | $18.66 | 2023 | Tepezza |
| Medtronic Minimed, INC. | $10.82 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sheldon Mckenzie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.